외용제 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Topical Drugs CDMO Market size is expected to reach USD 151.41 Billion in 2034 from USD 59.10 Billion (2025) growing at a CAGR of 11.02% during 2026-2034.

The Global Topical Drugs CDMO Market is growing steadily due to increasing outsourcing of drug development and manufacturing activities. Contract Development and Manufacturing Organizations (CDMOs) provide formulation, production, and packaging services for creams, gels, ointments, and transdermal patches. Rising demand for dermatological and pain management treatments is supporting market expansion. Pharmaceutical companies are increasingly relying on CDMOs to reduce costs and accelerate time-to-market.

Key growth drivers include the increasing prevalence of skin disorders and growing demand for personalized medicine. CDMOs offer specialized expertise, regulatory compliance, and scalable manufacturing capabilities. Advancements in topical drug delivery technologies are improving product effectiveness and stability. Additionally, rising demand for generic topical medications is strengthening outsourcing activities.

Looking ahead, the market is expected to benefit from expanding pharmaceutical pipelines and increased R&D investments. Emerging markets with developing healthcare industries will create new outsourcing opportunities. Companies are focusing on advanced formulation technologies and sustainable manufacturing practices. As pharmaceutical firms prioritize efficiency and innovation, the Global Topical Drugs CDMO Market is projected to experience consistent long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations)
• Liquid Formulations
• Transdermal Products
• Solid Formulations

By Therapeutic Area

• Dermatology
• Pain management
• Wound care
• Ophthalmology
• Other therapeutic areas

By Service Type

• Contract manufacturing
• Contract development

By End Use

• Pharmaceutical Companies
• Biotechnology Companies
• Other End Users

COMPANIES PROFILED

• Ascendia Pharmaceuticals, Bora Pharmaceuticals, Cambrex, Contract Pharmaceuticals, DPT Laboratories, MedPharm, PCI Pharma Services, Pierre Fabre Group, Piramal Pharma Solutions, The Lubrizol
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TOPICAL DRUGS CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Transdermal Products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Solid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TOPICAL DRUGS CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Pain management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Wound care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other therapeutic areas Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TOPICAL DRUGS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Contract manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Contract development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TOPICAL DRUGS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL TOPICAL DRUGS CDMO MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Therapeutic Area
  • 8.2.3 By Service Type
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Therapeutic Area
  • 8.3.3 By Service Type
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Therapeutic Area
  • 8.4.3 By Service Type
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Therapeutic Area
  • 8.5.3 By Service Type
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Therapeutic Area
  • 8.6.3 By Service Type
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TOPICAL DRUGS CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Ascendia Pharmaceuticals
  • 10.2.2 Bora Pharmaceuticals
  • 10.2.3 Cambrex
  • 10.2.4 Contract Pharmaceuticals
  • 10.2.5 DPT Laboratories
  • 10.2.6 MedPharm
  • 10.2.7 PCI Pharma Services
  • 10.2.8 Pierre Fabre Group
  • 10.2.9 Piramal Pharma Solutions
  • 10.2.10 The Lubrizol